A phase I study of cranial radiation therapy with concomitant continuous infusion paclitaxel in children with brain tumors

Li Liu, Neha Vapiwala, Louis K. Munoz, Naomi J. Winick, Steven D Weitman, Lewis C. Strauss, Lawrence S. Frankel, David I. Rosenthal

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Original languageEnglish
Pages (from-to)390-392
Number of pages3
JournalMedical and Pediatric Oncology
Volume37
Issue number4
DOIs
StatePublished - 2001

Fingerprint

Paclitaxel
Brain Neoplasms
Radiotherapy
Radiation-Sensitizing Agents
Glioma
Appointments and Schedules
Neuroepithelial Neoplasms
Cranial Irradiation
Taxoids
Astrocytoma
Chemoradiotherapy
Glioblastoma
Brain Stem
Hospitalization
Central Nervous System
Radiation
Brain

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Cancer Research

Cite this

Liu, L., Vapiwala, N., Munoz, L. K., Winick, N. J., Weitman, S. D., Strauss, L. C., ... Rosenthal, D. I. (2001). A phase I study of cranial radiation therapy with concomitant continuous infusion paclitaxel in children with brain tumors. Medical and Pediatric Oncology, 37(4), 390-392. https://doi.org/10.1002/mpo.1215

A phase I study of cranial radiation therapy with concomitant continuous infusion paclitaxel in children with brain tumors. / Liu, Li; Vapiwala, Neha; Munoz, Louis K.; Winick, Naomi J.; Weitman, Steven D; Strauss, Lewis C.; Frankel, Lawrence S.; Rosenthal, David I.

In: Medical and Pediatric Oncology, Vol. 37, No. 4, 2001, p. 390-392.

Research output: Contribution to journalArticle

Liu, L, Vapiwala, N, Munoz, LK, Winick, NJ, Weitman, SD, Strauss, LC, Frankel, LS & Rosenthal, DI 2001, 'A phase I study of cranial radiation therapy with concomitant continuous infusion paclitaxel in children with brain tumors', Medical and Pediatric Oncology, vol. 37, no. 4, pp. 390-392. https://doi.org/10.1002/mpo.1215
Liu, Li ; Vapiwala, Neha ; Munoz, Louis K. ; Winick, Naomi J. ; Weitman, Steven D ; Strauss, Lewis C. ; Frankel, Lawrence S. ; Rosenthal, David I. / A phase I study of cranial radiation therapy with concomitant continuous infusion paclitaxel in children with brain tumors. In: Medical and Pediatric Oncology. 2001 ; Vol. 37, No. 4. pp. 390-392.
@article{e3f7a86c6ec0457ebdf6444466e2f215,
title = "A phase I study of cranial radiation therapy with concomitant continuous infusion paclitaxel in children with brain tumors",
abstract = "Background. The prognosis of children with high-grade astrocytomas of the central nervous system is grim and has not been substantially improved by conventional chemoradiotherapy. We performed a multi-institutional phase I study to determine the toxicities and tolerance of concurrent external beam radiation of the brain and a unique dose-schedule of paclitaxel as a radiation sensitizer. Procedure. Paclitaxel was delivered intravenously as a continuous 24 h/ day, 7 days/week infusion during the entire 6-week course of fixed schedule standard radiation therapy. The dose of paclitaxel was escalated in patient cohorts in standard phase I design. Results. Eleven patients (eight brain stem gliomas, one glioblastoma multiforme, and two gliomatosis cerebri) were treated, Dose-limiting toxicity was encountered in the two patients treated at 6 mg/(m2/24 h), both of whom developed severe obstipation requiring prolonged hospitalization. Conclusions. We have shown in this first study of its kind that paclitaxel can be administered safely to children as a 6-week continuous infusion concurrent with cranial irradiation. The maximally tolerated and recommended phase II dose is 4 mg/ (m2/day). The benefits of taxanes as clinical radiation sensitizers for children with high-grade gliomas, if any, remain to be determined.",
keywords = "Malignant brain tumors, Paclitaxel, Radiosensitization",
author = "Li Liu and Neha Vapiwala and Munoz, {Louis K.} and Winick, {Naomi J.} and Weitman, {Steven D} and Strauss, {Lewis C.} and Frankel, {Lawrence S.} and Rosenthal, {David I.}",
year = "2001",
doi = "10.1002/mpo.1215",
language = "English",
volume = "37",
pages = "390--392",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - A phase I study of cranial radiation therapy with concomitant continuous infusion paclitaxel in children with brain tumors

AU - Liu, Li

AU - Vapiwala, Neha

AU - Munoz, Louis K.

AU - Winick, Naomi J.

AU - Weitman, Steven D

AU - Strauss, Lewis C.

AU - Frankel, Lawrence S.

AU - Rosenthal, David I.

PY - 2001

Y1 - 2001

N2 - Background. The prognosis of children with high-grade astrocytomas of the central nervous system is grim and has not been substantially improved by conventional chemoradiotherapy. We performed a multi-institutional phase I study to determine the toxicities and tolerance of concurrent external beam radiation of the brain and a unique dose-schedule of paclitaxel as a radiation sensitizer. Procedure. Paclitaxel was delivered intravenously as a continuous 24 h/ day, 7 days/week infusion during the entire 6-week course of fixed schedule standard radiation therapy. The dose of paclitaxel was escalated in patient cohorts in standard phase I design. Results. Eleven patients (eight brain stem gliomas, one glioblastoma multiforme, and two gliomatosis cerebri) were treated, Dose-limiting toxicity was encountered in the two patients treated at 6 mg/(m2/24 h), both of whom developed severe obstipation requiring prolonged hospitalization. Conclusions. We have shown in this first study of its kind that paclitaxel can be administered safely to children as a 6-week continuous infusion concurrent with cranial irradiation. The maximally tolerated and recommended phase II dose is 4 mg/ (m2/day). The benefits of taxanes as clinical radiation sensitizers for children with high-grade gliomas, if any, remain to be determined.

AB - Background. The prognosis of children with high-grade astrocytomas of the central nervous system is grim and has not been substantially improved by conventional chemoradiotherapy. We performed a multi-institutional phase I study to determine the toxicities and tolerance of concurrent external beam radiation of the brain and a unique dose-schedule of paclitaxel as a radiation sensitizer. Procedure. Paclitaxel was delivered intravenously as a continuous 24 h/ day, 7 days/week infusion during the entire 6-week course of fixed schedule standard radiation therapy. The dose of paclitaxel was escalated in patient cohorts in standard phase I design. Results. Eleven patients (eight brain stem gliomas, one glioblastoma multiforme, and two gliomatosis cerebri) were treated, Dose-limiting toxicity was encountered in the two patients treated at 6 mg/(m2/24 h), both of whom developed severe obstipation requiring prolonged hospitalization. Conclusions. We have shown in this first study of its kind that paclitaxel can be administered safely to children as a 6-week continuous infusion concurrent with cranial irradiation. The maximally tolerated and recommended phase II dose is 4 mg/ (m2/day). The benefits of taxanes as clinical radiation sensitizers for children with high-grade gliomas, if any, remain to be determined.

KW - Malignant brain tumors

KW - Paclitaxel

KW - Radiosensitization

UR - http://www.scopus.com/inward/record.url?scp=0034799120&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034799120&partnerID=8YFLogxK

U2 - 10.1002/mpo.1215

DO - 10.1002/mpo.1215

M3 - Article

C2 - 11568904

AN - SCOPUS:0034799120

VL - 37

SP - 390

EP - 392

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 4

ER -